ARTICLE | Clinical News

PARP ovarian data boosts Clovis

September 30, 2014 2:30 AM UTC

Clovis Oncology Inc. (NASDAQ:CLVS) gained $5.59 (13%) to $48.08 on Monday after presenting results from two trials evaluating rucaparib ( CO-338) for platinum-sensitive ovarian cancer at the European Society of Medical Oncology (ESMO) Congress in Madrid.

The oral inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) and PARP-2 achieved disease control rates of 93% in 20 patients with germline breast cancer early onset (BRCA) mutations in the Phase II portion of a Phase I/II trial evaluating 600 mg given twice daily. ...